Company Encyclopedia
View More
name
Autonomix Medical
AMIX.US
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc.
1.391 T
AMIX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. Stock Market Midday Update: The potential of targeted ablation therapy emerges, Autonomix Medical's stock price soars nearly 90%

    Autonomix Medical rose 89.57%; Intuitive Surgical fell 0.19%, with a transaction volume of USD 74.74 million; Abbott rose 0.38%, with a transaction volume of USD 60.76 million; SurModics rose 2.91%, with a transaction volume of USD 52.24 million; Boston Scientific fell 0.93%, with a market capitalization of USD 151 billion

    Tracking Unusual Activity·
    US
    AMIX
    +54.06%
    Tracking Unusual Activity·
    US
    AMIX
    +54.06%

    Autonomix Medical Reports Sustained Quality-of-Life Gains in Pancreatic Cancer Pain Study

    Autonomix Medical, Inc. (NASDAQ: AMIX) reported positive results from a subgroup analysis of its proof-of-concept study on targeted ablation therapy for pancreatic cancer pain. The study showed improvements in quality of life, symptoms, and functionality, with significant changes observed at 3 months post-treatment. These findings will guide the design of a future U.S.-based clinical trial set for 2026. The original content was published by Autonomix Medical on November 17, 2025.

    Reuters·
    US
    AMIX
    +54.06%
    Reuters·
    US
    AMIX
    +54.06%

    Autonomix Medical shares are trading higher after the company reported post-hoc subgroup analysis results from its first-in-human study showing potential quality-of-life improvements with its targeted ablation therapy.

    benzinga_article·
    US
    AMIX
    +54.06%
    benzinga_article·
    US
    AMIX
    +54.06%

    Promising Future for Autonomix Medical, Inc.: Buy Rating Backed by Clinical Progress and Strong Financials

    Analyst Anthony Vendetti of Maxim Group reiterated a Buy rating for Autonomix Medical, Inc., citing clinical progress, strong financials, and innovative technology. The company is advancing its market expansion study and microchip-based platform technology. Despite a recent 60.54% stock price drop, the analyst maintains a $5.00 price target, supported by a strong cash position and no debt.

    Tip Ranks·
    US
    AMIX
    +54.06%
    Tip Ranks·
    US
    AMIX
    +54.06%

    Autonomix Medical | 10-Q: FY2026 Q2 Revenue: USD 0

    LB filings·
    US
    AMIX
    +54.06%
    LB filings·
    US
    AMIX
    +54.06%